Shares of Australian diagnostic firm Genetic Technologies (GENE +33%) are ripping today on the...

|By:, SA News Editor

Shares of Australian diagnostic firm Genetic Technologies (GENE +33%) are ripping today on the back of a new bullish report issued by Australian investment bank Lodge Partner, starting the shares with a Buy and an aggressive $17 price target (that would make it a four-bagger from current levels). The firm says BREVAGen, GENE's key diagnostic product, is regaining momentum, noting that H2 sales rose 230% over H1, and it expects that trend to continue.